LEGN vs. ONC, TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, and SRPT
Should you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.
Legend Biotech vs.
Beigene (NASDAQ:ONC) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.
Legend Biotech has lower revenue, but higher earnings than Beigene. Legend Biotech is trading at a lower price-to-earnings ratio than Beigene, indicating that it is currently the more affordable of the two stocks.
Beigene has a net margin of -25.94% compared to Legend Biotech's net margin of -66.92%. Beigene's return on equity of -25.12% beat Legend Biotech's return on equity.
48.6% of Beigene shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 7.4% of Beigene shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Legend Biotech has a consensus target price of $79.50, suggesting a potential upside of 100.60%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Beigene.
Beigene has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500.
Legend Biotech received 85 more outperform votes than Beigene when rated by MarketBeat users.
In the previous week, Legend Biotech had 1 more articles in the media than Beigene. MarketBeat recorded 4 mentions for Legend Biotech and 3 mentions for Beigene. Legend Biotech's average media sentiment score of 1.36 beat Beigene's score of 0.50 indicating that Legend Biotech is being referred to more favorably in the news media.
Summary
Legend Biotech beats Beigene on 10 of the 17 factors compared between the two stocks.
Get Legend Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Legend Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:LEGN) was last updated on 2/21/2025 by MarketBeat.com Staff
Free LEGN Stock Alerts